Total Payments
$40,910
2024 Payments
$20.69
Companies
59
Transactions
472
Medicare Patients
13,493
Medicare Billing
$1.2M
Payment Breakdown by Category
Consulting$15,755 (38.5%)
Food & Beverage$12,853 (31.4%)
Travel$7,851 (19.2%)
Other$4,110 (10.0%)
Education$340.27 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,755 | 7 | 38.5% |
| Food and Beverage | $12,853 | 439 | 31.4% |
| Travel and Lodging | $7,851 | 8 | 19.2% |
| Honoraria | $4,000 | 2 | 9.8% |
| Education | $340.27 | 7 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110.00 | 1 | 0.3% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$40,910
464 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $13,504 | 73 | $0 (2023) |
| UroGPO LLC | $12,221 | 16 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $3,149 | 12 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $2,885 | 9 | $0 (2023) |
| Astellas Pharma US Inc | $2,247 | 90 | $0 (2023) |
| Dendreon Pharmaceuticals LLC | $985.39 | 22 | $0 (2022) |
| Endo Pharmaceuticals Inc. | $661.18 | 16 | $0 (2023) |
| TOLMAR Pharmaceuticals, Inc. | $428.21 | 14 | $0 (2022) |
| Amgen Inc. | $376.54 | 12 | $0 (2021) |
| Merck Sharp & Dohme LLC | $338.09 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.69 | 3 | Smith+Nephew, Inc. ($20.69) |
| 2023 | $1,164 | 48 | Merck Sharp & Dohme LLC ($193.75) |
| 2022 | $1,194 | 59 | Janssen Biotech, Inc. ($202.46) |
| 2021 | $2,602 | 56 | Bayer HealthCare Pharmaceuticals Inc. ($1,386) |
| 2020 | $3,039 | 48 | Bayer HealthCare Pharmaceuticals Inc. ($1,408) |
| 2019 | $12,085 | 90 | Janssen Biotech, Inc. ($6,581) |
| 2018 | $18,944 | 102 | UroGPO LLC ($8,039) |
| 2017 | $1,862 | 66 | Ferring Pharmaceuticals Inc. ($279.67) |
All Payment Transactions
472 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/10/2024 | Smith+Nephew, Inc. | STRAVIX (Medical Supply) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Extremities & Limb Restoration | ||||||
| 2024 | SN Holdings, LLC | — | — | — | $0.00 | Ownership |
| 2024 | SN Holdings, LLC | — | — | — | $0.00 | Ownership |
| 08/31/2023 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Urology Gynecology | ||||||
| 08/28/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Oncology | ||||||
| 08/25/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $22.88 | General |
| 08/24/2023 | Endo Pharmaceuticals Inc. | AVEED (Biological), XIAFLEX | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: UROLOGY | ||||||
| 08/23/2023 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), AVEED | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: UROLOGY | ||||||
| 08/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2023 | Endo Pharmaceuticals Inc. | AVEED (Biological), XIAFLEX | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: UROLOGY | ||||||
| 07/11/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: HORMONE THERAPY | ||||||
| 07/10/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: UROLOGY | ||||||
| 07/05/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 06/09/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2023 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $37.87 | General |
| Category: Oncology | ||||||
| 06/06/2023 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2023 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), AVEED | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: UROLOGY | ||||||
| 06/02/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug), LUTATHERA | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Oncology | ||||||
| 05/27/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 05/24/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $2.35 | General |
| 05/11/2023 | Endo Pharmaceuticals Inc. | AVEED (Biological), XIAFLEX | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: UROLOGY | ||||||
| 05/03/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: Oncology | ||||||
| 04/28/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Oncology | ||||||
| 04/26/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2023 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Diagnostic Imaging | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,775 | 13,641 | $802,954 | $251,490 |
| 2022 | 28 | 3,788 | 16,530 | $1.1M | $344,016 |
| 2021 | 27 | 3,603 | 17,859 | $1.1M | $348,005 |
| 2020 | 27 | 3,327 | 9,318 | $863,173 | $287,325 |
Total Patients
13,493
Total Services
57,348
Medicare Billing
$1.2M
Procedure Codes
112
All Medicare Procedures & Services
112 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 553 | 735 | $235,200 | $61,389 | 26.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 3,180 | $133,560 | $57,961 | 43.4% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 13 | 6,480 | $51,840 | $20,608 | 39.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 97 | 115 | $70,150 | $18,181 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 255 | 289 | $65,603 | $15,352 | 23.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 64 | 257 | $40,863 | $12,352 | 30.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 15 | 85 | $28,560 | $11,467 | 40.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 86 | 86 | $36,292 | $9,484 | 26.1% |
| 52356 | Crushing of stone of ureter with insertion of stent using an endoscope | Facility | 2023 | 25 | 26 | $27,586 | $8,898 | 32.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 43 | $14,663 | $4,545 | 31.0% |
| 52310 | Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | Office | 2023 | 18 | 19 | $15,371 | $4,494 | 29.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 54 | $9,666 | $3,459 | 35.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 697 | 1,032 | $7,224 | $3,204 | 44.4% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 359 | 451 | $11,726 | $3,098 | 26.4% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 19 | 23 | $9,108 | $2,675 | 29.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 107 | $8,667 | $2,615 | 30.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 27 | 58 | $5,684 | $2,354 | 41.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 271 | 340 | $2,040 | $1,994 | 97.7% |
| 51702 | Simple insertion of temporary bladder tube | Office | 2023 | 20 | 45 | $7,020 | $1,899 | 27.1% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 14 | 14 | $4,662 | $1,479 | 31.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 33 | $4,686 | $1,245 | 26.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 14 | 14 | $3,584 | $952.42 | 26.6% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 17 | 19 | $1,235 | $488.11 | 39.5% |
| 51700 | Simple bladder irrigation and/or instillation | Office | 2023 | 16 | 18 | $3,474 | $462.64 | 13.3% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 13 | 18 | $3,060 | $351.54 | 11.5% |
About Dr. Michael Grable, MD
Dr. Michael Grable, MD is a Urology healthcare provider based in Deland, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588614374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Grable, MD has received a total of $40,910 in payments from pharmaceutical and medical device companies, with $20.69 received in 2024. These payments were reported across 472 transactions from 59 companies. The most common payment nature is "Consulting Fee" ($15,755).
As a Medicare-enrolled provider, Grable has provided services to 13,493 Medicare beneficiaries, totaling 57,348 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 112 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Deland, FL
- Active Since 05/11/2006
- Last Updated 02/05/2021
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1588614374
Products in Payments
- Erleada (Drug) $15,414
- Nubeqa (Drug) $2,908
- XTANDI (Drug) $1,301
- PROVENGE (Drug) $1,028
- ERLEADA (Drug) $531.70
- MYRBETRIQ (Drug) $447.96
- ELIGARD (Drug) $442.61
- ZYTIGA (Drug) $416.70
- XIAFLEX (Biological) $390.12
- Prolia (Biological) $358.38
- KEYTRUDA (Biological) $338.09
- FIRMAGON (Drug) $279.67
- AVEED (Biological) $271.06
- Xtandi (Drug) $268.99
- LYNPARZA (Drug) $252.29
- Xofigo (Drug) $241.31
- BOTOX (Biological) $207.29
- Cook Medical Holmium Laser Fiber (Device) $190.09
- Myrbetriq (Drug) $157.88
- JEVTANA (Drug) $157.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.